We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PHAS
551
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $2.3M | 0.02% |
+619,434
| New | +$2.06M |
|
552
AutoZone
AZO
$50.2B
| $2.3M | 0.02% |
1,542
-3,665
| -70% | -$5.31M |
|
|
JNCE
553
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.29M | 0.02% |
337,398
+337,393
| +6,747,860% | +$2.8M |
|
554
Nucor
NUE
$56.4B
| $2.26M | 0.02% |
23,526
-28,028
| -54% | -$2.62M |
|
555
Cincinnati Financial
CINF
$28.5B
| $2.23M | 0.02% |
19,144
+10,893
| +132% | +$1.26M |
|
556
Trip.com Group
TCOM
$28.2B
| $2.23M | 0.02% |
+62,910
| New | +$2.4M |
|
|
AYX
557
DELISTED
Alteryx Inc
AYX
| $2.23M | 0.02% |
25,923
+17,878
| +222% | +$1.46M |
|
558
Paychex
PAYX
$41.1B
| $2.23M | 0.02% |
20,754
-962
| -4% | -$96.7K |
|
559
Hartford Financial Services
HIG
$38.4B
| $2.22M | 0.02% |
35,848
-163,808
| -82% | -$10.7M |
|
560
XP
XP
$8.65B
| $2.18M | 0.01% |
50,000
| – | – |
|
561
Yum! Brands
YUM
$40.7B
| $2.16M | 0.01% |
18,741
-13,425
| -42% | -$1.58M |
|
562
Wabtec
WAB
$50.8B
| $2.13M | 0.01% |
25,931
-35,801
| -58% | -$2.91M |
|
563
Marathon Petroleum
MPC
$91.2B
| $2.13M | 0.01% |
35,217
-6,090
| -15% | -$357K |
|
564
Match Group
MTCH
$9.05B
| $2.1M | 0.01% |
13,035
+381
| +3% | +$55.8K |
|
|
K
565
DELISTED
Kellanova
K
| $2.08M | 0.01% |
34,400
-28,035
| -45% | -$1.7M |
|
566
LKQ Corp
LKQ
$6.69B
| $2.07M | 0.01% |
+42,048
| New | +$2.01M |
|
567
Hewlett Packard
HPE
$63.8B
| $2.01M | 0.01% |
137,579
-19,528
| -12% | -$308K |
|
568
Akamai
AKAM
$16.4B
| $1.96M | 0.01% |
16,784
-35,069
| -68% | -$3.91M |
|
|
PXD
569
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.93M | 0.01% |
11,898
+2,412
| +25% | +$379K |
|
570
Pultegroup
PHM
$24.9B
| $1.93M | 0.01% |
35,316
-41,583
| -54% | -$2.32M |
|
571
EMQQ The Emerging Markets Internet & Ecommerce ETF
EMQQ
$265M
| $1.92M | 0.01% |
30,350
+4,290
| +16% | +$268K |
|
572
Ericsson
ERIC
$31.8B
| $1.92M | 0.01% |
152,517
-28,059
| -16% | -$376K |
|
573
Tilly's
TLYS
$117M
| $1.92M | 0.01% |
120,000
| – | – |
|
574
Verisk Analytics
VRSK
$27.1B
| $1.91M | 0.01% |
10,947
-68,597
| -86% | -$12.2M |
|
575
Omnicom Group
OMC
$23.5B
| $1.91M | 0.01% |
23,875
-24,231
| -50% | -$1.97M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.